Kintor Pharmaceutical KX-826 Phase 2 Results released

[Hyaenidae]

KX-826 Phase 2 Data Results​

The important statistical data results from Kintor’s KX-826 pyrilutamide phase 2 trial in males is:

• The trial comprised 120 male subjects with Norwood levels of 3V, 4, and 5.
• Cohorts included KX-826 2.5mg BID, 5mg QD, 5mg BID, and Placebo QD, BID.
• Primary endpoint was non-vellus target area hair count (TAHC) change from baseline to week 24.
• After 14 days of topical use, the blood concentration levels of KX-826 were 0.3 – 4.1 ng/ml, and its metabolite KX-982’s levels were 0.4 – 10.4 ng/ml.
• The incidence of adverse drug reactions was 16.1%, with the most common being pruritus or itchy skin. No serious adverse events or serious adverse drug reactions were reported.
• The most efficacious results were obtained in the group receiving 5mg of KX-826 BID (twice daily) which showed a 15.34 hair per cm² increase in TAHC above the placebo group, and a total increase of 22.73 hairs per cm² in TAHC compared to baseline.

These results will certainly be well received by the community of people seeking new treatments for hair loss and hair regrowth. Showing a 22 hair per cm² increase in non-vellus hair count, these results are easily comparable to past studies of oral finasteride. As a reminder, Kintor is also currently engaged in other KX-826 clinical trials, including a female phase 2 trial and male phase 3 trial in China, as well as a male phase 2 trial in the US.


tl;dr : A new drug as efficacious as oral finasteride without the side effects of finasteride.

@Heshan Daminda @emoji diaries

 

[Heshan Daminda]

ෆිනස්ටරයිඩ් තරම් අඩු ගානකට හම්බෙන්නේ නැහැල්ලු.

 

[kinkon]

බම්ප්